27,426 Shares in Encompass Health Corporation (NYSE:EHC) Bought by Nilsine Partners LLC

Nilsine Partners LLC purchased a new position in Encompass Health Corporation (NYSE:EHC - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 27,426 shares of the company's stock, valued at approximately $2,778,000.

Other large investors have also added to or reduced their stakes in the company. Colonial Trust Co SC bought a new stake in shares of Encompass Health in the 4th quarter worth approximately $29,000. Transce3nd LLC purchased a new position in shares of Encompass Health during the 4th quarter valued at $40,000. CBIZ Investment Advisory Services LLC grew its stake in shares of Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after acquiring an additional 127 shares during the period. Signaturefd LLC increased its holdings in Encompass Health by 21.6% in the 4th quarter. Signaturefd LLC now owns 704 shares of the company's stock worth $65,000 after acquiring an additional 125 shares during the last quarter. Finally, C M Bidwell & Associates Ltd. raised its stake in Encompass Health by 73.6% in the 4th quarter. C M Bidwell & Associates Ltd. now owns 750 shares of the company's stock valued at $69,000 after acquiring an additional 318 shares during the period. Hedge funds and other institutional investors own 97.25% of the company's stock.

Encompass Health Price Performance

Encompass Health stock traded up $0.79 during mid-day trading on Tuesday, hitting $121.01. 575,010 shares of the company traded hands, compared to its average volume of 703,100. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.06 and a current ratio of 1.06. Encompass Health Corporation has a one year low of $82.74 and a one year high of $123.13. The stock has a market cap of $12.20 billion, a price-to-earnings ratio of 25.69, a price-to-earnings-growth ratio of 2.44 and a beta of 0.89. The stock has a fifty day moving average price of $116.14 and a 200-day moving average price of $104.12.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The business had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.43 billion. During the same quarter in the prior year, the firm earned $1.12 earnings per share. The firm's revenue was up 10.6% on a year-over-year basis. On average, equities analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's payout ratio is presently 14.05%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on EHC shares. Royal Bank Of Canada lifted their target price on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research note on Monday, April 28th. KeyCorp raised their price target on Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a report on Tuesday, May 27th. Truist Financial reiterated a "buy" rating and issued a $135.00 price target (up from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Wall Street Zen cut Encompass Health from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, UBS Group lifted their target price on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $127.00.

Insiders Place Their Bets

In other Encompass Health news, CEO Mark J. Tarr sold 118,384 shares of the firm's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total value of $14,387,207.52. Following the sale, the chief executive officer now owns 527,070 shares of the company's stock, valued at $64,054,817.10. This trade represents a 18.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Patrick Darby sold 10,000 shares of the firm's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the completion of the sale, the executive vice president now directly owns 79,710 shares in the company, valued at $9,149,910.90. The trade was a 11.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 132,663 shares of company stock valued at $16,034,082 over the last three months. Insiders own 2.10% of the company's stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.